🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

88 results for “rituximab” Clear

  1. Rituximab

    First Tracks Biotherapeutics

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    3 trials

  2. Rituximab

    First Tracks Biotherapeutics

    Refractory Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. Rituximab 375 mg/m^2

    Takeda Pharmaceuticals International AG

    Mantle Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  4. SODIUM CHLORIDE , RITUXIMAB, MYCOPHENOLIC ACID

    Tour Hekla

    Intersitial lung disease related to systemic sclerosis

    phase 3 small molecule active

    1 trial

  5. VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, PIRTOBRUTINIB, VENETOCLAX

    Ology Bioservices Ireland LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    phase 3 small molecule active

    1 trial

  6. VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB

    Pharma Mar S.A.

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  7. VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE

    Celgene Europe Limited

    High-risk Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  8. recombinant human thrombopoietin (rhTPO); rituximab

    China SXT Pharmaceuticals

    Purpura

    phase 3 small molecule terminated

    1 trial

  9. rhTPO in combination with Rituximab

    China SXT Pharmaceuticals

    Purpura

    phase 3 small molecule completed

    1 trial

  10. rituximab; recombinant human thrombopoietin (rhTPO)

    China SXT Pharmaceuticals

    Purpura

    phase 3 small molecule completed

    1 trial

  11. six courses of zanubrutinib, rituximab and lenalidomide

    China SXT Pharmaceuticals

    Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  12. A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI

    Ology Bioservices Ireland LTD

    Primary Immune Thrombocytopenia

    phase 2 other active

    1 trial

  13. BENDAMUSTINE , CYTARABINE , VENETOCLAX , RITUXIMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. CYCLOPHOSPHAMIDE , RITUXIMAB , AB-101, FLUDARABINE

    Artiva Biotherapeutics

    Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Sjögren’s Disease (SjD)

    phase 2 small molecule active

    1 trial

  15. CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS, YTB323, CYCLOPHOSPHAMIDE, RITUXIMAB, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TOCILIZUMAB, RITUXIMAB

    Novartis Ophthalmics Europe

    Severe refractory idiopathic inflammatory myopathies (IIM)

    phase 2 small molecule active

    1 trial

  16. CYCLOPHOSPHAMIDE, PREDNISOLONE , Golcadomide, VINCRISTINE SULFATE, PEGFILGRASTIM, RITUXIMAB, Golcadomide, DOXORUBICIN, Golcadomide, VINCRISTINE SULFATE, RITUXIMAB, Golcadomide, PREDNISONE, BENDAMUSTINE HYDROCHLORIDE

    Celgene Europe Limited

    Newly Diagnosed Advanced Stage Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  17. CYCLOPHOSPHAMIDE, YTB323, FLUDARABINE PHOSPHATE, TOCILIZUMAB, RITUXIMAB, RITUXIMAB

    Novartis Ophthalmics Europe

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  18. CYTARABINE , LONCASTUXIMAB TESIRINE, RITUXIMAB, BENDAMUSTINE

    Fondazione Telethon ETS

    Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  19. DOXORUBICIN , CYCLOPHOSPHAMIDE , RITUXIMAB , POLATUZUMAB VEDOTIN , PREDNISONE , -, Zilovertamab vedotin

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  20. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  21. EPCORITAMAB, RITUXIMAB

    Daiichi Sankyo Europe GmbH

    Hematological Malignancies

    phase 2 small molecule active

    1 trial

  22. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  23. LENOGRASTIM , RITUXIMAB, BUSULFAN , FLUDARABINE , PLERIXAFOR , OTL-203

    Orchard Therapeutics (Netherlands) B.V.

    Mucopolysaccharidosis type I Hurler

    phase 2 small molecule active

    1 trial

  24. RECOMBINANT ADAMTS13 (rADAMTS13), -, RITUXIMAB

    Takeda Pharmaceuticals International AG

    Immune-mediated thrombotic thrombocytopenic purpura (iTTP)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources